
The study investigated the subcutaneous dual agonist BI 456906 for glucagon receptor and glucagon-like peptide 1 receptor in men with overweight/obesity. The study found that BI 456906 reduced body weight by up to 12.37% after 16 weeks of treatment and reduced plasma alanine and glucagon levels. However, treatment-related adverse events were reported in all participants receiving BI 456906, and 37% of participants treated with BI 456906 withdrew from dose escalation due to adverse events, most frequently decreased appetite.
Like
Save
Share